Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 13/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28734370 | 0.88 | KCNMA1 (0.82) | KCNMA1HDAC1MEN1KMT2ANPC1 | |
| SCHEMBL15437080 | 0.84 | KCNMA1 (0.68) | KCNMA1HDAC1MEN1KMT2ANPC1 | |
| SCHEMBL9775410 | 0.82 | KCNMA1 (0.78) | KCNMA1HDAC1MEN1KMT2ANPC1 | |
| SCHEMBL15437175 | 0.82 | KMT2A (0.60) | KCNMA1HDAC1MEN1KMT2AHPSE | |
| SCHEMBL14476825 | 0.81 | KCNMA1 (1.00) | KCNMA1HDAC1MEN1KMT2ANPC1 | |
| SCHEMBL3619439 | 0.80 | NPC1 (0.69) | KCNMA1HDAC1MEN1KMT2ANPC1 | |
| SCHEMBL329958 | 0.80 | KCNMA1 (0.77) | KCNMA1HDAC1MEN1KMT2ANPC1 | |
| SCHEMBL2025734 | 0.80 | NPC1 (0.52) | HDAC1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7292066 | 0.79 | KCNMA1 (0.69) | KCNMA1HDAC1MEN1KMT2ANPC1 | |
| SCHEMBL5033350 | 0.79 | KCNMA1 (0.69) | KCNMA1HDAC1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053428-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-21 | — | — | US | disclosed |
| US-20170260139-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260139-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260139-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | US | disclosed |
| US-9688636-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| US-9688636-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-2875003-B1 | NEW 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS UND THEIR USE | Bayer Pharma AG (DE) | 2016-11-16 | — | — | EP | disclosed |
| EP-2875003-B1 | NEW 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS UND THEIR USE | Bayer Pharma AG (DE) | 2016-11-16 | — | — | EP | disclosed |
| US-20150148376-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| US-20150148376-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| US-8981104-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-17 | — | — | US | disclosed |
| US-8981104-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-17 | — | — | US | disclosed |
| US-8981104-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-17 | — | — | US | disclosed |
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | TNNT2, TNNI3, FABP3 | KCNMA1 2838/4885HDAC1 2938/4885MEN1 4576/4885 |
| US-10053428-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | TNNT2, TNNI3, FABP3 | KCNMA1 3125/4885HDAC1 2834/4885MEN1 4510/4885 |
| US-20170260139-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | TNNT2, TNNI3, FABP3 | KCNMA1 2838/4885HDAC1 2938/4885MEN1 4576/4885 |
| US-20150148376-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | TNNT2, TNNI3, FABP3 | KCNMA1 2838/4885HDAC1 2938/4885MEN1 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.